Molecular Analysis of Thrombocytopenia and Cancer (MATAC): Investigating Antigenic Mimicry Between Platelets and Tumor Cells in Patients With Immune Thrombocytopenia (ITP) Associated With Cancer

NCT06444477 | Completed

• 1 other identifier: CHUBX 2024/16
• Study Type: observational
• Target: 33
• Locations: 1 country
• Sites: 20

Brief Summary

The association between hematologic malignancies and ITP is well described, but this link is much less clear with solid cancers. In cases of ITP associated with cancers, specific cancer treatment can lead to remission or even cure of ITP. Thus, our hypothesis was that chronic expression of GPIIB by tumor cells could have initiated an autoimmune loop against GPIIB, leading to the onset and perpetuation of ITP.

Conditions

Neoplasms; Immune Thrombocytopenia; Immune Thrombocytopenic Purpura; Cancer

Keywords

Proteomics; Mortality; Side Effects; Multicenter; Retrospective

Outcome Measures

Primary Outcomes (1)

• Remission rate of ITP at 6 months after specific cancer treatment

  At baseline (Day 0)

Secondary Outcomes (7)

• All-cause mortality

  At baseline (Day 0)

• Side effects related to ITP and its treatment

  At baseline (Day 0)

• Side effects related to its treatment

  At baseline (Day 0)

• Clinical description of the characteristics of ITP associated with a diagnosis of solid cancer

  At baseline (Day 0)

• Biological description of the characteristics of ITP associated with a diagnosis of solid cancer

  At baseline (Day 0)

Study Arms (1)

Patients with a definite diagnosis of both ITP and cancer

Other: ITP and cancer

Interventions

ITP and cancer OTHER

ITP and cancer

Patients with a definite diagnosis of both ITP and cancer

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with a definite diagnosis of both ITP and cancer

You may qualify if:

• Adult patients with a definite diagnosis of both ITP and cancer;
• Synchronous diagnosis of ITP and cancer;
• Onset of ITP occurring 6 months before or after the diagnosis of cancer.

You may not qualify if:

• None

Sponsors & Collaborators

• University Hospital, Bordeaux: lead

Study Sites (20)

AP-HP Hôpital Jean Verdier service de médecine interne

Bondy, France

Location

CHU de Clermont-Ferrand - service de médecine interne

Clermont-Ferrand, France

Location

AP-HP Hôpital Mondor service de médecine interne

Créteil, France

Location

AP-HP Hôpital Bicêtre service de médecine interne

Le Kremlin-Bicêtre, France

Location

CHU de Lille - service d'Hématologie

Lille, France

Location

HCL - service d'Hématologie

Lyon, France

Location

AP-HM Hôpital la Timone - service de médecine interne

Marseille, France

Location

CHU de Montpellier - service d'Hématologie

Montpellier, France

Location

CHRU de Nancy - service de Médecine Interne et Immunologie Clinique

Nancy, France

Location

CHU de Nantes - service de médecine interne

Nantes, France

Location

CHRU d'Orléans - service de Médecine interne

Orléans, France

Location

CHRU d'Orléans - service de réanimation

Orléans, France

Location

AP-HP Hôpital Bichat service de médecine interne

Paris, France

Location

AP-HP Hôpital Saint-Antoine service de médecine interne

Paris, France

Location

AP-HP Hôpital Saint-Louis service immuno-hématologie

Paris, France

Location

CHU de Bordeaux Service de Médecine Interne et Maladies Infectieuses

Pessac, France

Location

CHU de Poitiers - service de médecine interne

Poitiers, France

Location

CHRU de Strasbourg - service de médecine interne

Strasbourg, France

Location

CHU de Toulouse - service de médecine interne

Toulouse, France

Location

CHU de Tours - service de médecine interne

Tours, France

Location

MeSH Terms

Conditions

Purpura, Thrombocytopenic, Idiopathic; Neoplasms

Interventions

Inosine Triphosphate

Condition Hierarchy (Ancestors)

Purpura, Thrombocytopenic; Purpura; Blood Coagulation Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Thrombotic Microangiopathies; Thrombocytopenia; Blood Platelet Disorders; Cytopenia; Hemorrhagic Disorders; Autoimmune Diseases; Immune System Diseases; Hemorrhage; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Skin Manifestations; Signs and Symptoms

Intervention Hierarchy (Ancestors)

Inosine Nucleotides; Purine Nucleotides; Purines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds; Nucleotides; Nucleic Acids, Nucleotides, and Nucleosides; Ribonucleotides

Study Officials

• Etienne RIVIERE, MD

  University Hospital, Bordeaux

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 14, 2024
• First Posted: June 5, 2024
• Study Start: August 13, 2024
• Primary Completion: September 15, 2025
• Study Completion: September 15, 2025
• Last Updated: January 26, 2026

Record last verified: 2026-01

Locations

FR (20)